Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops for dry eye pass safety check in small trial

NCT ID NCT06660290

Symptom relief Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the safety of AR-15512 eye drops in 55 people with dry eye disease. Participants received the drops at different temperatures and with eyes open or closed to see if these factors affect side effects. The goal was to measure how many people had eye-related side effects from the drops.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AR-15512 ophthalmic solution (also called TRYPTYR or Acoltremon)
What this could lead to
If successful, this could confirm that AR-15512 eye drops are safe and comfortable for treating dry eye disease.
What could go wrong
This is a small safety study with only 55 people, so results may not apply to everyone. It does not test how well the drops work for symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

55 people

The number who actually took part.

Started

Jan 2025

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Corrected Visual Acuity (Snellen) 20/200 or better in both eyes; * Good general and ocular health, as determined by the Investigator using medical history, ophthalmic examination and history; * Capable of giving signed informed consent. * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Current evidence of other clinically significant ophthalmic disease other than dry eye; * History of ocular surgery within 1 year of the Study Visit; * Use of any topical ocular anti-inflammatory medications (for example, Restasis®, Cequa™, Vevye™, Xiidra®), other prescription ophthalmic product for dry eyes, topical ocular corticosteroid, or non-steroidal-anti-inflammatory agents within 30 days of the Study Visit; * Positive pregnancy test or currently breastfeeding. * Other protocol-defined exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease

Contacts and locations

Locations

  • Advancing Vision Research, LLC

    Smyrna, Tennessee, 37167, United States

  • Andover Eye Associates

    Andover, Massachusetts, 01810, United States

  • Eye Research Foundation

    Newport Beach, California, 92663, United States

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Total Eye Care, PA

    Memphis, Tennessee, 38119, United States

  • Vision Institute

    Colorado Springs, Colorado, 80907, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.